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2.1 A comparison of the true treatment effect without screening θ0 = e
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PH model (2.12) vs. the time-dependent true treatment effect θt under screening
(2.13). Top left: Baseline hazard function h. Top right: The distribution (pdf with
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2.2 True and large-sample characteristics in screened and unscreened populations under
various shapes of the baseline hazard. Left: The baseline hazard in the unscreened
population h(t) and its counterpart under screening λ(t) averaged over the lead
time W as in (2.5). Right: True hazard ratio in the unscreened population θ0, its
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In recent years, rapid development of modern biomarker research and continuous
growth of public interest in early prevention and treatment of cancer have resulted
in an increased use of early detection programs (screening). These developments
have led to a dramatic increase in the incidence of early stage diagnoses, most of
which would have never happened within the patient’s lifespan without screening
(overdiagnosis).
Screening interventions interact with the latent disease progression process. First,
the diagnostic test sensitivity increases as the disease progresses and becomes easier
to detect. Second, early detection advances the diagnosis by the amount of the so-
called lead time (Zelen and Feinleib, 1969) which adds to the patient’s survival, and
the disease presents at an earlier stage with more favorable clinical characteristics.
Third, slower progressing diseases are easier to catch by the test (length-bias, Zelen
and Feinleib (1969)) while they are still latent, while aggressively developing disease
usually results in diagnosis due to symptoms (clinical diagnosis) rather than the test
(screening diagnosis). As a result of the diagnostic intervention, the population is
split into less aggressive diseases diagnosed by the test (length bias) and the more
aggressive ones missed by the test (anti-length bias, Zelen (2004)).
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To improve cancer control policy under limited resources, a quantitative mea-
sure of the effectiveness of cancer screening and treatment interventions is needed.
Two dimensions define the success of cancer control interventions: the population
dimension (cancer incidence, distribution of the disease presentation at diagnosis,
cancer mortality) and the subject-specific level (subject’s prognosis based on clinical
information available at diagnosis and knowledge of the disease heterogeneity and
utilization of screening in the population from which the subject was sampled).
One way to assess the benefit of screening is via randomized screening trials.
However, such trials need to recruit a lot of patients for a long period of time to
be able to have sufficient power to compare outcomes. They are also conditional on
specific screening patterns, and the results cannot be generalized to other populations
without use of modeling.
The randomized clinical trial (RCT) is the gold standard to evaluate treatment
effects. Randomization is believed to be a tool to obtain a conservative test in the
presence of confounding, unbiased under the null hypothesis (Schumacher et al.,
1987; Gail et al., 1984; Struthers and Kalbfleisch, 1986). However, as we show in this
study, dependent on the model, the estimated treatment effects could be biased (not
necessarily conservatively) if important covariates are not controlled for specifically
in a model-based analysis.
These consideration lead us to pursue a statistical modeling approach to evaluate
cancer screening and treatment interventions. Investigators from the Cancer Inter-
vention and Surveillance Modeling Network (CISNET, http://cisnet.cancer.gov/), of
which we are part of, use statistical modeling to study the effects of cancer control
interventions on population trends in incidence (Etzioni et al., 1999, 2002; Draisma
et al., 2003; Davidov and Zelen, 2004; Tsodikov et al., 2006) and mortality (Berry
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et al., 2005; Lee and Zelen, 2008). Other researchers (Parker et al., 2006) developed
statistical models to study disease progression and survival for screened detected
patients. The challenge of modeling is that a shallow statistical model cannot ex-
plain the observed phenomena and the results cannot be generalized to populations
under different screening patterns. Complex simulations on the other hand are over-
parameterized and need to rely on many ad-hoc parameter specifications based on
outside sources and literature. Our approach is to use mechanistic statistical mod-
eling in conjunction with statistical inference methods to leverage the precision and
confidence of statistical methodology and the explanatory and predictive power of
mechanistic models.
The objective of this dissertation is to develop quantitative measures of the im-
pact of early detection followed by treatment on clinical outcomes and to evaluate
the success of the combined screening and treatment interventions. We extend our
previous work on marginal and stage/grade specific incidence model (Tsodikov et al.,
2006; Chefo and Tsodikov, 2009) and build a joint hierarchical family of models of
prostate cancer from the point of onset to the point of death. Using the models we
study the heterogeneity induced by screening interventions in the population, and
its interaction with treatments applied at diagnosis of the disease as they affect the
clinical and disease outcomes such as disease prognosis and cancer mortality. Our
models are statistical in nature and are fit to observed population and subject-level
data before predictions are made.
The rest of the dissertation is divided as follows:
• Chapter 2. We assess how the the early detection of cancer affects
the outcome from clinical trials.
4
Cancer-specific survival measured from the point of diagnosis is the most com-
mon endpoint in cancer clinical trials and observational studies. Early detection
of cancer leads to variability of the point of diagnosis advanced by the amount
of the so-called lead time, a random variable. Estimated treatment effects by
the proportional hazards (PH) model may be biased if this variability is ignored.
Three distinct problems studied in this chapter are of interest with this specific
model misspecification mechanism: (1) How the true multiplicative treatment
effect differs in screened vs. unscreened populations; (2) How they are estimated
using a misspecified model (PH); (3) How the bias and standard errors can be
corrected using a meta-analytic approach that does not require the raw data.
To address these questions we use a joint cancer incidence and survival modeling
approach and illustrate it using simulation and real prostate cancer data. To
reduce the dependence on raw data, a small treatment effect approximation to
the asymptotic inference with a misspecified PH model is pursued.
• Chapter 3. We develop an analytic joint statistical model of cancer
incidence, presentation at diagnosis, and progression.
We develop a statistical model for the natural history of the disease and its
interaction with screening. The model can be decomposed into four major com-
ponents: (1) The marginal incidence model with age at prostate cancer diagnosis
as an endpoint. Its outcome is the prostate cancer incidence as a functional of
the distributional characteristics of screening utilization process operating in
the population. (2) A model of disease presentation at diagnosis (stage and
grade of the disease). The disease presentation at diagnosis can be considered
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a multivariate mark to the point process of diagnoses of prostate cancer in the
population. Combined with the marginal incidence model this model gives a
marked point process model describing the stage and grade (Z) specific inci-
dence. The model predicts the probability of being diagnosed with a specific
stage and grade at cancer incidence. (3) The disease progression model is the
main contribution of this chapter. It defines the probability of disease progres-
sion for the early detected patient after the screening diagnosis. Understanding
this model is critical for measuring how the early treatment intervention enabled
by the early diagnosis favorably affects the patient’s prognosis. For patients de-
ciding to defer treatment, the model gives an assessment of the risk of disease
progression under watchful waiting (conservative management of the disease).
Treatment effects built into the progression model define the benefit by way of
preventing the development of more advanced stages of the disease, the so-called
stage shift.
• Chapter 4. We develop an analytic joint statistical model of survival
post-diagnosis and cancer mortality in the presence of screening and
treatment interventions.
We apply the models developed in Chapter 3 to characterize the heterogeneity
of the prostate cancer patient population and describe the latent disease char-
acteristics for the US male population. This information is used as a frailty for
modeling survival post-diagnosis adjusted for the lead-time and length bias, and
to adequately describe the treatment effects in the situation of variable point
of diagnosis modulated by screening operating in the population. We then
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synthesize all the models into the mortality model by integrating out the inter-
mediate outcomes of cancer diagnosis, stage, grade, treatment and survival. We
also estimate the risks of potential adverse events for prostate-specific antigen
(PSA)-detected patients given the prognostic factors at the time of diagnosis.
The model is also used to estimate the treatment efficacy of radiotherapy and
radical prostatectomy against watchful waiting and study how treatment effects
are influenced by the early detection programs. All analyses use data from the
Surveillance, Epidemiology and End Results (SEER) database.
In our final chapter, we summarize the strengths and the limitations of our current
approach and discuss the direction for future research.
CHAPTER II
Treatment Effect under Early Detection of Cancer
2.1 Introduction
Cancer is one of the top five causes of death in the US and in many developed
countries. To reduce cancer mortality and cancer burden, combined use of the early
detection and more effective treatments has become the major trend of cancer inter-
ventions. Rapid development of modern biomarker research in recent years makes
cancer screening tests more sensitive than ever, and we are seeing cancers that were
never detectable before. Early detection advances cancer diagnosis by the amount
of the lead time, a random variable. This results in over-diagnosis of the disease,
increasing cancer incidence and seemingly improved survival from the point of diag-
nosis even if treatment is not effective.
The most common approach in cancer clinical trials and observational studies is
to use the proportional hazards (PH) model to estimate the multiplicative treatment
effect. The model is fitted to cancer-specific survival time measured from the point
of diagnosis.
Suppose the PH model is a valid one in an unscreened population. Then in the
screened population, the PH model is misspecified because cancer-specific survival
includes an additive random lead time effect. When the effect of the lead time is
7
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integrated out, the model changes its form because the link function of the PH model
is a nonlinear one. Model misspecification, including one induced by random effects,
received considerable attention in the literature. Kempthorne (1977) and Fienberg
(1980) showed that collapsing a contingency table results in a biased estimator for a
binary response outcome. Gail et al. (1984) further summarized asymptotic biases
for common models in the exponential family GLMs when important covariates were
omitted. They showed that the asymptotic bias is not zero unless the model is linear
or exponential. Similar effects were observed with the PH models for failure time
data. Lagakos and Schoenfeld (1984) demonstrated how ignored covariates result in
a reduced power of the log-rank test; Schumacher et al. (1987) and Gail et al. (1984)
showed a conservative bias in the proportional hazards setting and Struthers and
Kalbfleisch (1986) studied biased treatment effect under a misspecified PH model
when the true model is accelerated failure time or when an important PH covariate
is omitted.
In this study, we build on the studies of a general misspecified PH model by
assessing the bias of the variance estimator, deriving a small treatment effect Taylor
approximation, developing a meta-analytic correction of the biases, and studying a
specific misspecification pattern associated with ignoring the heterogeneity induced
by the early detection of cancer.
1. We will study the true multiplicative effect. In the correctly specified PH model,
the true hazard ratio is independent of time. We assume that this model op-
erates in an unscreened population. When the model is misspecified, in the
screened population, the true hazard ratio becomes time dependent. We will
study the direction and the magnitude of the difference between the two multi-
plicative effect measures in Section 2.4.
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2. It is a common practice to fit the PH model regardless of whether patients
are recruited in the screening era or not. We will study the bias measuring
the difference between the true hazard ratio in the unscreened population and
what the PH estimator is consistent for under screening, in Section 2.5. Note
that because PH model is misspecified for the screened population, it estimates
neither the unscreened hazard ratio nor the true time-dependent hazard ratio
under screening correctly.
3. Correct estimation of the treatment effect can be accomplished by fitting the
right model to raw survival data. However, obtaining raw data from a series of
international clinical trials is a logistical challenge. Besides, the correct model
reproducing treatment effects in the presence of lead time is a subject of sci-
entific debate. Alternatively, we propose a simplified meta-analytic approach
that allows us to approximately correct the bias without using raw data from
the clinical trial. We assume that covariate effects (treatment) are small, and
approximate the bias in point estimates and standard errors up to the first order
term. Characteristics of the unscreened population and the distribution of the
lead time necessary to perform the correction are estimated using large sample
cancer registry data and cancer incidence models, and are assumed known in a
relatively small sample analysis of a clinical trial. This leads to an approximate
correction for the bias in Section 2.6
2.2 The model, notation, assumptions and preliminaries
Let g, G, λ, Λ denote the density (pdf), the survival function (sf), the hazard
function (hf), and the cumulative hazard function (chf) of the true model, respec-
tively. We assume that the true model is a departure from a PH model explained by
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unobserved heterogeneity summarized by a frailty random variable (r.v.) W , possi-
bly a vector. Given W , the baseline survival distribution is represented by the pdf
f , sf F , hf h, and chf H. The effect of treatment r.v. Z is modeled via an expo-
nential predictor θ(β, z) = exp(βz), where β is a vector of regression coefficients.
For example, Z may represent a binary treatment assignment in a clinical trial, dose
of the treatment agent, or generally any set of variables characterizing the specific
treatment of the disease.
At the complete data level (given W ) the model is
(2.1) λ(t|Z,W ) = θ(Z)h(t|W ), G(t|Z,W ) = F (t|W )θ(Z), g = λG, Λ = − logG.
The misspecified PH model is an average of the complete data model (2.1)
(2.2) λ(t|Z) = E{λ(t|Z,W )|Z, T > t}, G(t|Z) = E{G(t|Z,W )|Z},
where expectations are taken over the conditional distribution of W , given Z, and T
is the survival time being modeled.
In the sequel, for brevity, we will suppress the arguments t, Z,W of the functions
such as λ(t|Z,W ) or h(t|W ), and assume that they are evaluated at the true β0 unless
noted otherwise and explicitly. Also, we will use explicit notation for conditional
expectations introduced in Tsodikov (2003). Define a relative expectation as
(2.3) E(µ||ν) = E(µν)
E(ν)
for any functions µ and ν of some random variables. The notation is motivated by
the representation
(2.4) E{µ(X)|A} = E{µ(X)1A(X)}
E{1A(X)}
,
where X is a random variable, A is a measurable event, 1A is an indicator of the
event (=1 if X ∈ A, and 0 otherwise), and E{1A(X)} = Pr{A}. We arrive at (2.3)
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by substituting a general function ν for 1A(X) in (2.4), and observing that (2.3) is
still a conditional expectation. Indeed, the right part of (2.3) is an integral of µ(x)








Note that the probability measure Pν,X(dx) represents a length-biased distribution
of X so that the relative expectation could be written as a conditional expectation
referring to the condition characterizing the length biased sampling of X. However,
this interpretation is irrelevant when no length biased sampling is actually going on
in the data. We use the relative expectation to avoid defining an artificial length
biased sampling scheme with the only purpose of wanting to use conventional con-
ditional expectation notation for some expressions that look like the right part of
(2.3). Besides we use convenient algebra associated with (2.3) as described in the
Appendix. The convenience of this notation is that it explicitly expresses a condi-
tional expectation through unconditional ones without having to define a random
variable that induces the conditional probability measure. For example, instead of
conditioning on T > t when averaging the hazard function among survivors at t in
(2.2), we can write explicitly using (2.3),
(2.5) λ(t|Z) = E{λ(t|Z,W )||G(t|Z,W ), Z} = E{λ||G,Z} = θE{h||F θ, Z}.
Here E{µ||ν, Z} is interpreted as (2.3) where all expectations are conditional on
r.v. Z in the usual sense. Note that for any non-random ν, or when µ = µ(X),
and ν = ν(Y ), and X⊥Y , we have E(µ||ν) = E(µ). Under the PH model h and F
in (2.5) are non-random, so E{h||F θ, Z} = h leading to the natural PH expression
λ = θh.
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Presented in Appendix are useful properties of the relative expectation (2.3) and
its derivatives that will be used throughout the paper.
Of primary interest in the example will be a model misspecification induced by
the lead time. Lead-time measures how much a clinical diagnosis due to symptoms
is advanced as a result of early detection by a screening test. With W playing the
role of the lead time, we have the specific model
(2.6) h(t|W ) = h(t−W )1{t>W}.
Note that this simple expression implies a number of important assumptions.
1. In the absence of screening when diagnosis occurs clinically due to symptoms
(CDx), the model is characterized by a non-random baseline hf h(t). When
patient’s diagnosis is advanced by screening by the amount of the lead time W ,
survival during the lead time is guaranteed as patients do not die before they
develop symptoms. Hence their hf is zero during the lead time as specified by
the 1{T>W} term in (2.6). In the sequel we will omit 1{T>W} for brevity assuming
that h(t|W ) = 0, t ≤ W .
2. In the presence of screening, survival time distribution cannot be exponential,
because h(t|W ) cannot be a constant in t unless it is uniformly zero.
3. For the same reason, h cannot be a decreasing function of t without being
uniformly zero.
4. The support of survival time in the presence of screening is affected by the
missing variable W . This is a key distinction of model (2.6) from other mis-
specification models considered in the literature.
5. In a screened population, some patients are still detected clinically either be-
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cause they were not screened, or because their cancer was missed by screening.
Such patients by definition have W = 0 with probability 1, hence the distribu-
tion of W has a mass at 0 (see Figure 2.1, top right). Expression (2.6) presumes
that survival of an early detected patient can be decomposed into the survival to
the point when the patient would be detected clinically, plus the survival of the
unscreened patient. In (2.6) the survival pattern post projected point of CDx
(represented by the form of baseline hf h) is the same as without screening.
The bias and variance meta-analytic correction will be based on the following
simplifying assumptions.
Assumption II.1.
1. Random variables Z and W are independent Z⊥W ;
2. Censoring is independent of W ;
3. True treatment effects β0 are small so a first order Taylor approximation with
respect to β0 can be used.
While not essential for theoretical expressions, Assumption II.1 allows one to
adjust reports based on the PH model analysis using knowledge of first three moments
of Z only, without having to hypothesize multivariate distributions of Z, W and the
survival time, by meta-analysis. Having to specify the multivariate distributions
would defeat the purpose of meta-analysis essentially requiring a fit of the correct
mixed model to raw data or a poorly justified guess.
2.3 Lead-time
Distribution of the lead-time W is a crucial piece of input for the analysis of this
paper. It is estimated in Tsodikov et al. (2006) from population and cancer incidence
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data amassed in the Surveillance, Epidemiology, and End Results (SEER) cancer
registry (www.seer.cancer.gov). Let λI(a |x) be the hazard function (incidence rate)
of cancer diagnosis at age, A = a, for a person born in year x. Cancer development
passes through the disease-free state and the pre-clinical state before being detected
or censored without a diagnosis. The subject’s age at tumor onset AO represents the
duration of the disease-free stage. The duration of latent cancer growth in the pre-
clinical stage is given by the delay time ξD = A− AO, a backward recurrence time,
represented by the period between cancer onset at the age of AO and its diagnosis
at the age of A. Given onset time, cancer diagnosis is a result of two competing
risks, the time to detection by screening, ξSDx, and the time to clinical diagnosis due
to symptoms of the disease, ξCDx, so that the delay time is ξD = min(ξSDx, ξCDx).
The time ξCDx is referred to as the sojourn time. Conditional ξCDx given screen
diagnosis, is stochastically larger than the unconditional one, due to the length bias.
If the unconditional ξCDx is exponential then the conditional will be larger by a
factor of 2 by the lack of memory property and symmetry. Suppose A = {a1, a2 . . . }
are random ages when the subject is screened (a screening schedule). We have used
a two-stage model for the screening schedule point process A. Let λ1S(a, t) be the
hazard of the first Prostate-Specific Antigen (PSA) test for a man of age a in year t.
Then the probability that a man born in year x will not be tested by the age of a is








We assume that in men who already had their first PSA tests, secondary tests
{a2, a3 . . . } form a non-homogeneous Poisson process with intensity λ2S(a, t). Both
intensities of PSA testing λ1S and λ2S are treated as known bivariate functions es-
timated by approximating the output of a random schedule generator developed by
the National Cancer Institute (NCI) Mariotto et al. (2007).
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The survival function GSDx(ξ |x,AO) representing the probability of no screening
diagnosis for a subject born in year x, with tumor onset at the age of AO, and delay
time since onset ξ is derived in Tsodikov et al. (2006) as
GSDx(ξ |x,AO) = G1S(AO + ξ |x) + [1−G1S(AO |x)]G2SDx(ξ |x,AO, AO) +∫ ξ
0
[1− α(ζ)]f1S(AO + ζ |x)G2SDx(ξ − ζ |x,AO + ζ, AO)dζ,(2.8)
where α is age-dependent screening sensitivity, and
(2.9)











= 0 for any b ≤ a. The above expressions are a result of averaging over A and
the Bernoulli outcomes of screening tests with probability of success α within the
subject, given AO. Using conditional independence of the competing risks of cancer
diagnosis by screening and clinically, given age at tumor onset AO, we have





GCDx(a− AO |x,AO)GSDx(a− AO |x,AO)
}
,
where GCDx is the survival function of the sojourn time.
This model was fitted by maximizing a parametric likelihood for incidence rates.
The joint distribution (pdf) of the lead time W = ξCDx − ξSDx, a forward recur-
rence time, and age at diagnosis A is given by
fLT (w, a|x) =
∫ a
0
fO(y|x)fCDx(a− y + w|x, y)
 GSDx(a− y|x, y), w = 0fSDx(a− y|x, y), w > 0
 dy,
where fO is a pdf of the age at onset, and fCDx, fSDx are pdfs corresponding to sf
GCDx, GSDx, respectively. Expression under the integral is a joint pdf of age at onset
y, screen diagnosis at a, and potential clinical diagnosis at a+ w.
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Finally, the conditional lead-time distribution used in this paper is obtained from
the joint one




where fI is the pdf corresponding to the cancer incidence rate λI . Shown in Figure
2.1 is a representative lead time distribution for a 65 year old patient diagnosed in
1995 predicted by the incidence model Tsodikov et al. (2006).
2.4 The true multiplicative treatment effect of a misspecified model
Assuming that in the reference group corresponding to no treatment θ(zref) = 1,
let θ(Z) represent the hazard ratio in the correctly specified PH model (the one
without screening)
(2.12) λ(t|Z) = θ(Z)h(t).








Define a correction factor, the true multiplier m(t |θ) characterizing the effect of
model misspecification on the hazard ratio






When the treatment is effective (i.e. θ < 1), m(t | θ) > 1 implies that the actual
treatment effect is smaller than θ, so the effect is conservatively attenuated. On the
other hand, m(t | θ) < 1 means that the actual treatment effect is larger than θ0 so
the effect is anti-conservatively attenuated.
Key to the properties of the multiplier are given by the following two lemmas.
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Lemma II.2. The logarithmic derivative of the multiplier is proportional to the
relative covariance between the negative baseline cumulative hazard -H = logF and
the baseline hf h.
(2.15)










∣∣∣∣F θ, Z} .
The result follows from (2.36) in the Appendix.
Lemma II.3. A version of Chebyshev’s inequality (See Shea (1979)). Let u(x) and
v(x) be functions and W be a random variable such that E{u(W )}, E{v(W )}, and
E{u(W )v(W )} exist. Then
1. if u and v are both nonincreasing or both nondecreasing then
Cov(u(W )v(W )) ≥ 0
2. if one of u and v is nonincreasing and the other nondecreasing then
Cov(u(W )v(W )) ≤ 0
3.
Cov(u(W )v(W )) = 0
if and only if at least one of u and v is a constant.
The following observations follow immediately from (2.14). When m(t | θ) = 1,
there is no bias, θt = θ. Clearly, m(t | θ) = 1 uniformly in t when there is no treatment
effect (θ = 1). Also, m(t | θ) → 1 as t → 0, indicating that there is no bias at the
start of follow up.
When the baseline hazard h, is an increasing function, u(x) = h(t|x) = h(t−x)1t>x
is decreasing in x while v(x) = −H(t − x) is increasing. By Lemmas II.2, II.3 the
18
logarithmic derivative is negative so m(t | θ) is a decreasing function of θ. This
implies that θt is biased conservatively toward the null hypothesis θ = 1. Indeed
since m(t | 1) = 1, in the left neighborhood of θ = 1 we have m(t | θ) > 1, and
consequently 1 > θt > θ at least when θ is close to 1. Alternatively, when θ > 1
(treatment is harmful) we still have attenuation towards the null as θ > θt > 1.
With small treatment effects when θ is close to 1 (2.15) gives the departure of the
multiplier from 1. Indeed, expanding m(t|θ) around β = 0 we have





(θ − 1) + o(1)







It is important to note that u(x) cannot be made an increasing function of x,
because u(x) = 0 for x ≥ t by definition, and h is nonnegative. If, for the sake of
argument, this were possible, then by Lemma II.3 we would have optimistic (anti-
conservative) bias with decreasing hazard. Also, under the same fantasy, by the last
statement of Lemma II.3 and the fact that H cannot be a constant, exponentially
distributed survival in the absense of screening (h = Const) would be the only case
of no bias uniformly in t. The unbiasedness under exponential survival would hold
regardless of the size of the treatment effect by virtue of (2.14). None of these
scenarios can take place because h(t|x) = 0, x ≥ t. However, they help understand
the behavior of m under non-monotonic h. Generally, when h is non-monotonic,
the direction of the bias term defined by the multiplier, m(t|θ), depends on the
shape of the hazard function h, and the distribution of the lead time W . Averaging
over W will weigh increasing and decreasing areas of h against each other as they
contribute to the opposite behavior patterns of m. The result will depend on the
weights provided by the form of the pdf of W , conditional on survival up to t.
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For cancers where cure is a possibility, such as prostate cancer, the hazard function
typically increases initially but turns into decreasing one eventually, as with any cure
model h(t) → 0 as t → ∞. Note that over-diagnosed cancers contribute greatly to
the chance of ’cure’.
The treatment in a screened population may appear more efficient than it actually
is, dependent on the time t when the effect is evaluated. Shown in Figure 2.1 is the
multiplier behavior for a unimodal baseline hazard function for various values of θ of
the treatment effect and under the lead time distribution shown in the upper right
corner of the figure as estimated in Tsodikov et al. (2006) and outlined in Section
2.3. Note that there is one point in the follow-up time around 18 years when the
true average multiplicative treatment effect is unbiased.
The behavior of the bias described in this section is more complicated than in the
case of misspecification induced by ignored PH covariates (Lagakos and Schoenfeld,
1984; Gail et al., 1984; Struthers and Kalbfleisch, 1986; Schumacher et al., 1987)
that always leads to a conservative bias. This is because in the latter case the mixed
effect is not in the argument of the possibly non-monotonic h.
2.5 Estimating treatment effects using a misspecified PH model
2.5.1 Assessing the bias of point estimates
In Section 2.4, we studied how the true treatment effect is modified by the early
detection. However, when the effect is estimated by the misspecified PH model, the
PH estimator is generally consistent for some hazard ratio that is neither the true
underlying hazard ratio θ0, nor the average true hazard ratio θt. The estimators will
depend on the duration of the study τ . We assume that τ is non-random and marks
the right extreme of the time to censoring. Denote by θ∗(τ), β∗(τ) the large sample
limits of the estimators θ̂, β̂ based on fitting the misspecified PH model.
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Figure 2.1: A comparison of the true treatment effect without screening θ0 = e
β0 under the PH
model (2.12) vs. the time-dependent true treatment effect θt under screening (2.13).
Top left: Baseline hazard function h. Top right: The distribution (pdf with mass at
zero) of the lead time W . Bottom: The true multiplier, a ratio (2.14) of the true effect
under screening averaged over the lead time to the effect without screening.













































Let X be time to event (failure or censoring) measured from observed diagnosis
(CDx or SDx whichever comes first), and δ = 1failure is an indicator of failure (=1
if failure, =0 if censoring). The data is represented as a sample of independent
triplets (Xi, δi, zi), i = 1 · · ·n, where z is a vector of treatment covariates, and Z
the corresponding random vector. For an individual i define the counting processes
Yi(t) = I(Xi ≥ t), Ni(t) = I(Xi ≤ t, δi = 1). Define an empirical analog of the
relative expectation E{Z||θ(β)GS}, where G,S are the true survival functions for
time to failure and censoring, respectively, as





The score function for the partial likelihood PL (Cox, 1972) can be written as









zi − Ê{Z||θ(β), Y }
}
dNi(t),
where β is the regression coefficient (an arbitrary argument), and τ is the duration
























Ê{Z||θ(β), Y } p→ E{Z||θ(β)GS},
where G,S, g are parameterized by the true β0, and β is a placeholder for the MLE
of β, the solution to the score equation. Using (2.18), after a little algebra, the large
sample limit of the normalized score function 1
n
Un(τ, β) (2.17) can be written as

















= E{Z||B} −E{Z||A}. Notation aside, this expression is the same
as in Struthers and Kalbfleisch (1986). As noticed in Section 2.2, multiplying a
condition by a non-random quantity does not change the relative expectation (2.3).
Therefore under the PH model conditioning on gS and on θGS are equivalent be-







uniformly zero when β = β0, a reflection of the fact that the PH estimation equation
is consistent (Andersen and Gill, 1982). Under a misspecified PH model, the maxi-
mum partial likelihood estimator (MPLE), β̂(τ) solving (2.17)=0 will be consistent
for β∗(τ, β0), the solution of the score equation (2.19)=0. Generally, the MPLE es-
timator from the misspecified PH model, β̂(τ), is biased β∗(τ, β0) 6= β0. It is easy
to verify that β̂ is unbiased under the null hypothesis β0 = 0. This follows from the
fact that in this case θ0 = 1, and the conditions gS = hFS and θGS = FS are both







(2.19) are equal (at β = β0 = 0) to the unconditional E{Z} making the difference
zero. In other words when θ0 = 1 then β = 0 is the solution to t he score equation
(2.19)=0.
Note that if β0 6= 0 even under exponential baseline survival β0 still does not
satisfy (2.19) because of the implicit presence of 1{T>W} in h making it dependent
on W through the support of survival times. Explicitly, in this case
g = θhE{I{W<t}F θ|Z} 6= θhG = θhE{F θ|Z},
and consequently E{Z||θGS} 6= E{Z||λGS} = E{Z||gS}, all because of the indica-
tor function resulting in G = E{F θI{W<t}|Z}+ Pr{W ≥ t|Z}.
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2.5.2 Small treatment effect approximation for point estimates
By definition the function β∗(β0) is obtained by solving U
∗(β|β0) = 0 with respect
to β (dependence on τ is suppressed for brevity). Hence, taking derivative with












where ≡ is uniform equality with respect to β0. Expanding β∗(β0) around β0 = 0
and keeping in mind that β∗(0) = 0 we get
(2.21) β(β0) = β
∗′(0)β0 + o(β0),
where the prime stands for a partial derivative with respect to β0. The first order
approximation is





The PH multiplier, m∗(τ) = β∗
′
(τ, 0), describes the departure of β∗ from β0.
m∗(τ) = 1,m∗(τ) > 1, and m∗(τ) < 1 indicate that the effect is unbiased, overesti-
mated, or underestimated, respectively. Combining (2.20) and (2.21) we obtain






Taking derivatives in (2.23) using (2.19), Lemma II.6 in the Appendix, and under

















Here V ar(Z) is thought of as the covariance matrix if Z is a vector. By Lemma II.5











indicating that the behavior of m∗ is also governed by the covariance of instanta-
neous and cumulative hazards conditional on survival up to t (compare with Section
2.4). Note that if censoring does not depend on the treatment covariates Z, S will
cancel from (2.24), and the bias will not depend on the censoring distribution. The
PH multiplier m∗ is a multiplicative modifier of β0. In terms of hazard ratio, we ex-
pect the limit treatment effect estimated by the PH model to be θ∗(τ) ≈ θm
∗(τ)
0 . For
a population under screening, the estimator obtained from the PH model is biased
with respect to either the underlying treatment effect θ0 or the actual treatment effect
θt represented by (2.13). Given θ0, the relationship between true and large sample
quantities h(t), λ(t), θt, and θ
∗(τ) is displayed in Figure 2.2. The large-sample limit
of PH estimated hazard ratio θ∗(τ) depends on the distributions of the underlying
survival from the clinical diagnosis, and the lead time (2.24). The PH multiplier also
depends on the duration of the study.
2.5.3 Measuring the bias of variance estimated by the PH model
Using the general setting of the M-estimation (Van der Vaart (2000), Chapter 5)
and assuming regularity conditions hold, we have
√
n(β̂(τ)− β(τ, β0))
d→ N (0,Σ∗(τ, β0)) ,
where β̂(τ) is the MLE under a misspecified PH model and
















is the covariance matrix, ` = logPL, `1 is a contribution of one observation to the
likelihood, and the expression is evaluated at β = β∗(τ, β0), the limit in probability of
PH-model based solution. The weak convergence result stated above is valid despite
the presense of ‘nuisance’ estimator Ê{Z|θ(β), Y } in the profile score function (2.17)
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Figure 2.2: True and large-sample characteristics in screened and unscreened populations under
various shapes of the baseline hazard. Left: The baseline hazard in the unscreened
population h(t) and its counterpart under screening λ(t) averaged over the lead time W
as in (2.5). Right: True hazard ratio in the unscreened population θ0, its time-dependent
counterpart under screening θt, and θ
∗(τ) ≈ θm
∗(τ)
0 representing the large-sample limit
of the PH-estimated hazard ratio under screening. τ is the duration of the study; t ≤ τ
is a point in follow-up time. Note that the misspecified PH model produces a biased
estimate θ̂(τ)
p→ θ∗(τ) of the average true hazard ratio θt under screening. Computation
of m∗ is done under the Assumption II.1 approximation.




























































































































the information matrix estimated when the misspecified PH model is fitted to the
data. Proceeding similar to Section 2.5.1, after some algebra, the variance of the
individual score in the middle of the sandwich (2.25) is
(2.27) Σ∗1
def












where U∗1 = ∂`1/∂β. If the model is correctly specified, Σ
∗(τ, β) = I−1(τ) because
I = Σ∗1. Indeed, similar to the discussion after the score equation (2.17), under
the PH model or under the null hypothesis, the relative expectation difference term
in the right part of (2.27) is zero, and relative variances in (2.27) and (2.26) are
equal. However, generally the correct variance of the misspecified model is given
by I−1Σ∗1I
−1 6= I−1, and the variance reported as I−1(τ) using the PH model is
incorrect.
2.5.4 Small treatment effect approximation for the variance
Now, consider the variance (2.25) under the small treatment effect Assumption
II.1. Using the lemmas presented in the Appendix we have the expansions
E{gS} = E{fS}+ E{ZfS}[1− E{H||f}]β0 + o(β0)








Var{Z||θSG} = Var{Z||S}+ [m∗ − E{H||f}]M3{Z||S}β0 + o(β0),
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The after some algebra we get the expansion for the variance in the form
(2.30) Σ∗ = I−10 − I−10 [I1 + I2 + 2I3 − 2I5I4I−10 ]I−10 β0 + o(β0).
Note that for the PH model, a similar but simpler exercise gives the following variance
approximation
(2.31) Σ∗ = I−10 − I−10 [I1 + I2]I−10 β0 + o(β0).
There are at least two scenarios when the PH variance is unbiased. Naturally, if
the true model is PH (no misspecification), then I3 = I4 = 0, and (2.30) and (2.31)
are equivalent. A non-trivial fact, however, is that when Z is not skewed, i.e. when
M3{Z||S} = 0, then I1 = I3 = I5 = 0, (2.30) and (2.31) are also equivalent and
equal to
(2.32) I−10 − I−10 I2I−10 β0 + o(β0).
Also, when censoring is independent of the covariates, it is easy to see that (2.31)
28
and (2.30) are the same so that the PH model based variance is correct up to the
first order of β.
2.6 The meta-analytic correction
We have shown that estimators in the PH model are generally biased under mis-
specification. To correct the bias, we consider a meta-analytic framework to restore
the adjusted hazard ratio θ0 from the results of reported studies without access to
raw patient-level data. Let ŝ2i be the sample variance of the estimated treatment
effect coefficients, β̂i, in study i and ωi be the weight assigned to that study where
ωi = 1/ŝ
2
i , i=1 · · · k. If the distribution of the treatment covariate is not symmet-
ric, the reported sample variance needs to be corrected as well as discussed in the
sections 2.5.3, 2.5.4. The meta-analytic estimate β̂ is obtained as a weighted average
of study-specific β̂i with weights inversely proportional to the sample variance of the












Since the MPLE estimator from the PH model, β̂, is a consistent estimator of
β∗(τ, β0), approximately, by the Continuous Mapping Theorem, θ̂0(τ) = exp([β̂/m
∗(τ)]z)
is also a consistent estimator for θ0 (subject to approximating Assumptions II.1). Let
σ2 denote the variance of β̂. By the Delta method, we will have
√

































Alternatively, one could exercise the correction of each study first, and then pro-
vide a meta-analytic estimate based on the corrected individual study estimates.
This is preferable if studies being combined have different durations.
2.7 Simulation study
We used simulations to study the accuracy of the PH multiplier under small
treatment effect assumption. Sensitivity analyses were also conducted to evaluate
how the shape of the baseline hazard and the magnitude of the treatment effect affect
the estimated hazard ratios.
We adopted a 2×2 design to estimate the hazard ratio of the treatment group
versus the control group using the PH model for both the unscreened and the screened
populations. For the unscreened population, the survival time was calculated from
the time of clinical diagnosis to time of death. For the screened population, a random
lead time W was generated using the distribution displayed in Figure 2.1 and was
added to the survival time in agreement with the specific convolution model (2.6).
Under the PH assumption, a pre-specified treatment effect θ0 = exp(β0) was applied
to treatment group characterized by the z = 1 value of the dummy variable. Survival
times from the clinical diagnosis were drawn from Weibull distributions for increasing
and decreasing baseline hazards, or from a cure model distribution for a changing
baseline hazard. Survival functions of Weibull and cure model distributions were
parameterized using median, m, and shape, s, parameters, and the treatment effect





















Hazard Ratios were estimated using the PH model. Subjects with survival times
longer than τ were censored. Adjusted hazard ratios were calculated using the PH
multiplier defined in (2.24) and were compared with the true result. Two hypothetical
treatment groups with the sample size of 500 each were used. For one replicate
survival data in the treatment and control group was generated under no screening
and under screening. Hazard ratios θ0 (no screening) and θ
∗(τ) (under screening)
were estimated by the PH model applied to both sets of the data. To obtain an
approximately unbiased estimate of θ0 under a misspecified model, the log hazard
ratio estimate under screening θ̂(τ) was adjusted by dividing it by the small-sample
approximated multiplier m∗(τ) given by (2.24). The r.v. Z was taken to represent
treatment assignment in a 1:1 ratio by simple randomization, a Bernoulli(0.5) r.v.
Censoring was assumed to be independent of Z so S cancels from (2.24). Baseline
distribution characteristics H and f were assumed to be known externally. The
experiment was repeated for various study durations τ . Shown in Figure 2.3 are the
results of a study to assess the quality of the proposed adjustment based on the small
treatment effect approximation. The left part of the figure shows three scenarios of
varying shape of the baseline hazard function without screening vs. under screening
(averaged over W ). The right part of the figure shows hazard ratios estimated or
predicted under different study durations represented by the x-axis. The wiggly
polygon curves in the right part of the figure give estimated hazard ratios without
screening (the bottom curve), and the one under screening showing a departure
upwards. The smooth curves (a line at y = θ0 in the case of no screening) going
through the polygons represent an average or a large sample limit of the respective
PH estimate. In the case of screening, the latter is given by the exponentiated
solution of (2.19)=0 with respect to β under the true β0, H, S. The top dashed curve
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Table 2.1: Empirical vs. approximate variance (θ0 = 0.5, τ=15, n=10000)
Proportion of the




Increasing h(t), Weibull m=5, s=1.5
Näıve variance 7.45 6.04
Sandwich variance 7.42 6.00
Approximated variance 6.93 5.68
Decreasing h(t), Weibull m=5, s=0.9
Näıve variance 9.62 7.49
Sandwich variance 9.61 7.48
Approximated variance 9.31 7.50
Non-monotonic h(t), Cure m=3, s=2
Näıve variance 12.52 9.65
Sandwich variance 12.55 9.68
Approximated variance 11.30 8.90
shows hazard ratio under screening predicted as θ
m∗(τ)
0 with the multiplier m
∗(τ)
obtained from the approximation (2.24). It is clear from Figure 2.3 that the bias
correction using the approximation to the multiplier is reasonably accurate except
perhaps in the case of large treatment effects (small θ0).
We also conducted a simulation study to compare the difference between the
corrected variance, Σ∗, and the variance reported by the PH model using the inverse
of information matrix. Having generated a large sample of 10000 we found that when
the treatment is effective (i.e. θ0 < 1), the difference between the adjusted and naive
variance is quite small (< 1%) regardless of the treatment allocation ratio (table
2.1).
2.8 Example: Radical prostatectomy vs. watchful waiting for prostate
cancer
Radical prostatectomy is an invasive surgical procedure to remove the prostate
gland. It is one of the most common treatments for patients with localized prostate
32
Figure 2.3: Quality of the small treatment effect approximation for the misclassification bias.
Left:Shapes of the baseline hazard function without screening h vs. under screening
λ. Middle and right column: Variable polygons and smooth curves going through them
correspond to PH model estimated and average hazard ratios at various study dura-
tions τ . The lines at y = θ0 correspond to a simulation without screening (W = 0 with
probability 1). The dashed curve showing a departure upwards particularly with small
θ0 (large beneficial treatment effect) is the hazard ratio under screening predicted using
the approximation (2.24) for the multiplier.


















































































































































































cancer. Three studies, one from Europe (Bill-Axelson et al., 2005) and two from the
United States (Tewari et al., 2006; Albertsen et al., 2007), have looked at large groups
of localized prostate cancer patients. All patients in these three studies were newly
diagnosed and many of them must have been subjected to the Prostate-Specific Anti-
gen (PSA) tests, especially those diagnosed in the United State after 1990. Relative
effects of radical prostatectomy vs. watchful waiting (conservative management) on
the disease-specific survival were estimated using PH models. Assuming that the
study cohorts are similar to patients in the Surveillance, Epidemiology, and End
Results (SEER) registry data, and that the recruitment is following the pattern of
cancer incidence in the SEER population, we recovered the underlying treatment ef-
fects θ0 for radical prostatectomy vs. watchful waiting using the methods described
in Section 2.6. Distribution of the lead time was obtained from the marginal inci-
dence model (Tsodikov et al., 2006) fitted to SEER data, and assumed known. The
baseline hazard was obtained from a PH analysis of SEER data before the year of
1988 when PSA was introduced, and assumed known for prediction of the multiplier.
The lead time and survival distributions depend on age, A, and year of diagnosis,
Y . Therefore we incorporated age and calendar time as covariates into the lead time
and into the baseline survival characteristics essentially by tabulating their distribu-
tions for all combinations of A and Y . We then exploit the fact that we kept the
development general with respect to how h(t|W ) depends on W . Therefore, we can
redefine the vector W to include A, Y in addition to the lead time. Essentially this
means that all expectations over W turn into expectations over W,A, Y , and the
key expressions of the paper are valid with this understanding. These expectations
were taken with respect to the lead time conditional on A, Y , and then over the
empirical distribution of A, Y specified using SEER data and the calendar period of
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Table 2.2: Estimated and predicted relative risks of radical prostatectomy vs. watchful waiting
Study Reported RR(95%C.I.) RR(95%C.I.)
from PH model after correction
Bill-Axelson et al. (2005, NEJM) 0.56 (0.36-0.88) 0.51 (0.24-0.77)
Tewari et al. (2006, J. Urology) 0.37 (0.25-0.55) 0.35 (0.21-0.50)
Albertsen et al. (2007, J. Urology) 0.29 (0.16-0.52) 0.23 (0.07-0.39)
Combined result from meta-analysis 0.41 (0.31-0.53) 0.37 (0.26-0.51)
the respective study. The results of the predicted true underlying treatment effects
from all the three studies as well as the combined estimate using meta-analysis are
summarized in table 2.2.
This analysis indicates under-estimated treatment effects by major clinical studies.
However, the correction appears to be relatively modest, 6-26% relatively to the
corrected one. Note that the corrected hazard ratio refers to the survival time from
clinical diagnosis (the point of diagnosis by symptoms), for which there is no direct
data if the patient is screen detected while asymptomatic.
2.9 Discussion
When screening is operating in the population targeted by clinical trials, the PH
model is misspecified due to the fact that the time of diagnosis is advanced by a
random and unobserved amount, the lead time, as patients are detected before they
develop symptoms of the disease. This type of misspecification is special because
patients do not die before they develop symptoms (during the lead time) meaning
that the support of the survival time is random.
While early detection might enhance the treatment effect (i.e. interact with treat-
ment), we have conservatively assumed that screening is of no real benefit, and we
asked the narrow question of what the implications of misspecification might be in
this situation and how they can be reversed or at least reduced without access to
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raw data.
We have shown that even with proper randomization, evaluating the treatment
effect in clinical trials recruiting from a population under screening could result in
biased estimates. The bias is a function of the duration of the study, the shape of
baseline hazard, the lead time distribution in the population under screening, the
distribution of time to censoring if it varies by treatment group, and the size of the
true treatment effect.
Unlike the bias from omitting important covariates in the PH model, the bias
from ignoring early detection is not always conservative. To correct the treatment
effect estimated by the misspecified PH model, we propose a meta-analytic frame-
work based on a study of bias and variance of a general misspecified PH model. To
be able to provide a correction in the absence of raw data we entertained a small
treatment effect approximation that simplified the formulas and reduced the com-
plexity of information needed to launch the correction. Simulation results suggest
the correction we proposed is robust and accurate in realistic scenarios of modest
treatment effects.
We also found that the PH model is correct at estimating the variance if the
distribution of treatment covariates is not skewed. At the same time under no cir-
cumstances other than absence of screening can the PH model point estimate of the
treatment effect be unbiased.
This study also shows that a correction of the treatment effects observed in the
screening era is possible using population models of cancer that provide an estimate
of the distribution of the lead time. This distribution was assumed to be known
throughout the paper. This is a natural assumption since population models are
fitted to big populations while the survival study of this paper concerns much smaller
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groups of cancer patients only.
A number of simplifying assumptions were unavoidable. We disregard stage pro-
gression between screening and clinical diagnosis in a small fraction of patients. We
did not incorporate the interaction between treatment and early detection result-
ing in the perceived benefit of screening to the population. Last but not least, as
we focused on the lead time bias, the length bias for screen-detected cancers and
anti-length bias for cancers missed by screening were ignored. The latter can be
recognized from (2.6) that implies, for example, that h(t|W = 0) apply equally to
a patient from an unscreened population or to a patient from a population under
screening who is detected due to symptoms with zero lead time. Length bias ex-
hibits itself in that screening is more likely to catch slower growing tumors that
spend longer times without symptoms. As a result tumors detected by screening
have better prognosis than tumors missed by screening. For this reason a patient
with W = 0 from an unscreened population generally has better prognosis than a
screened patient with W = 0 whose cancer was missed by screening. This effect can
be incorporated by allowing more complicated forms of h(t|W ) such as h(t−W,W ),
where the second W models dependence on the lead time on top of the convolution
effect. The same recipe could be used to generally model baseline survival post clini-
cal diagnosis as being correlated with the lead time. Note that we intentionally kept
the development of the theoretical sections of the paper general with respect to the
form of h(t|W ) to incorporate such scenarios.
To avoid massive over-treatment of cancer patients, screen-detected patients with
good prognosis may be placed on deferred treatment regimen. Screening and treat-
ment would then eventually represent a dynamic cancer control strategy designed to
preserve the mortality benefit while reducing over-treatment. Joint dynamic models
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need to be developed to analyze the combined screening and treatment interventions.
2.10 Appendix
2.10.1 Properties of relative expectation








∣∣∣∣νθ} = Cov{µ, log ν||νθ}
E{µ||νθ}
.
Proof proceeds straightforwardly by differentiation and using the definition (2.3).
Lemma II.5. Let µ, ν, and ξ be some functions of random variables. Define
(2.37) E {µ| |νξ } = E{µ||ν} − E{µ||ξ}.
Then




Proof. Using the definition (2.3) of the relative expectation we get the left part
of (2.38) as a difference of two fractions. Bringing them to a common denominator
and gividing numerator and denominator by E(ν), and again using (2.3), we arrive
at the right part of (2.38).
Lemma II.6. Let µ be some function of random variables, Z be some random vari-
able, and θ = eβZ. Define the central relative moment of Z of kth order as










Proof. The proof proceeds by induction, uses straightforward differentiation and















Proof by straightforward differentiation.
CHAPTER III
Predicting Cancer Progression and the Null Hypothesis of
Treatment Effect under Screening
3.1 Introduction
Deciding whether, or how, to treat cancer for a newly diagnosed prostate cancer
patient is difficult because a large fraction of patients are over-diagnosed and if
left untreated would never die from the disease. Quantifying potential risks of the
disease progression would provide valuable information to help patients and doctors
make informed decisions to manage cancer. With screening in place, patients are
detected earlier in a less advanced stage showing longer survival from the point of
diagnosis even in the absence of any treatment benefit, which greatly complicates
treatment decisions. Because the risk of cancer detection is correlated with the latent
cancer growth process, patient heterogeneity at diagnosis varies dependent on the
utilization of screening in the population from which the patient is sampled. Thus,
the construction of a disease progression prognosis for the patient depends on joint
modeling of the cancer development and heterogeneity in the population and the
subject-specific risk of cancer progression within the patient given the information
on his latent heterogeneity available through clinical and demographic characteristics
observed at diagnosis.
Since the introduction of PSA test in 1988, the wide spread use of screening
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programs resulted in profound dynamics of cancer incidence and its presentation
at diagnosis. In the PSA era survival post-diagnosis has “improved” counteracting
the effect of increased incidence (Nicholson and Harland, 2002). The severity of
the disease at diagnosis (stage and grade) has also enjoyed a favorable shift. Due
to overdiagnosis there is an increase in the probability of “cure” in prostate cancer
(Draisma et al., 2003; Tsodikov et al., 2006; Draisma et al., 2009). Neither lead-time
nor overdiagnosis can be directly observed so their estimation requires modeling.
Parker et al. (2006) developed a competing-risks model to estimate the prostate
cancer survival for screen-detected prostate cancer. While the model by Parker et al.
(2006) adjusts for the lead-time, it conditions on stage and grade at diagnosis. Since
stage and grade at diagnosis are themselves affected by screening, it is difficult to
generalize the results to populations with different screening utilization patterns.
Also, the model does not incorporate a progression mechanism and cannot predict
the chance that cancer will become metastatic or high-grade if left untreated before
symptoms appear, a piece of information important for treatment decisions.
The general problem that has not been addressed is that of the null hypothesis of
treatment effect when patients are recruited from populations under variable patterns
of screening. Consider the same patient run through two scenarios: screening and
no screening under the hypothesis of no treatment benefit. Despite being under
the null hypothesis we will have different survival post-diagnosis, different stage
and grade of the disease at diagnosis in the two scenarios, and it is not trivial to
formulate the treatment effect in this setting. However, because we are picturing the
same patient running through both scenarios, and because screening is not curative
without the treatment effect, the age at which symptoms appear (CDx) and survival
past that point is the same in both runs. For a screen-detected patient, at the
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point of observed screening diagnosis (SDx), the future cancer history resulting in
the onset of symptoms, CDx, and a possibly more advanced stage and grade at that
point, represents a multivariate random outcome. This outcome is the same under
the null hypothesis of treatment effect or under the assumption that patient is not
treated and is blinded to the fact of cancer diagnosis that we call the counterfactual
ignored screening scenario (iS). Needless to say, the iS scenario is never observed in
practice. Note that patients on conservative management or active surveillance are
not equivalent to iS because of self-selection, subsequent monitoring, and medicine
they still receive while on the regimen. It is clear that the null hypothesis of treatment
effect is that of the same joint distribution of age, stage and grade at CDx, and same
survival post CDx where CDx is understood as the point of observed diagnosis for
the patient detected by symptoms, and a counterfactual CDx under the iS scenario
for the screen-detected patient. We will give a rigorous definition later.
To address the problems mentioned above we propose a joint model for the disease
presentation at SDx and real or counterfactual CDx. We build upon the “marginal”
stage and grade specific incidence model describing disease presentation at the ob-
served point of diagnosis (either CDx or SDx, but not both on the same patient).
We will use our model to describe prostate cancer related risks for the general
US male population and the potential adverse events for a PSA-detected man given
information at the time of diagnosis. The details of the model are discussed in sec-
tion 3.2 and the expressions for key natural history events are explained in section 3.3.
Finally, we provide predictions for natural history events using population data and
the results are shown in section 3.4.
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3.2 Natural history model
The natural history model is based on the classical three-state chronic disease
model. The disease progresses through three states, disease-free state, pre-clinical
state, and clinical state. The disease is chronic and the transitions are irreversible.
On top of that there is a finer characterization of cancer progression through stage
(Localized vs. Metastatic) and grade (Low vs. High). The model is partially specified
and does not assume any specific mechanism of progression through stage and grade.
The duration of the disease-free state is represented by the age at tumor onset,
described by the random variable Y . We assume there is no prostate cancer before
the age of 50, so the age origin in the model resides at 50.
The pre-clinical state in the absence of screening measures the time period be-
tween tumor onset and detection via clinical symptoms appearing (clinical diagnosis,
CDx). This duration is called the sojourn time. In the presence of screening, can-
cer may be detected while it is still asymptomatic by the screening test (screening
diagnosis, SDx). Time to the two types of diagnosis TCDx and TSDx, respectively,
represent competing risks originating at the age of Y . The clinical state describes
the survival time Ts from the time of diagnosis (CDx or SDx) to the time of cancer-
specific death. The structure of the chronic disease three-state model are shown in
figure 3.1. Our approach is to build a series of hierarchical models to describe prostate
cancer incidence, presentation at diagnosis (Z = Stage and Grade), progression, and
survival.
3.2.1 Marginal incidence model
The marginal incidence model describes the risk of being diagnosed with prostate
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Die from prostate cancer
(aM)
Chronic Disease Three-State Model
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Figure 3.1: Structure of the chronic disease three-state model
44
previous paper, the prostate cancer incidence for x birth cohort (a cohort of men
turning 50 in year x) can be written as a complex mixture model (Tsodikov et al.,
2006) where missing data include the age at onset y, the screening schedule, and the
detection process. The p.d.f. of cancer diagnosis given birth year x can be written
as
(3.1) fI(aI |x) =
∫ aI
0
fo(y|x)fI(aI − y|x, y) dt
where fo is the unconditional pdf of age at tumor onset, and fI(aI − y|x, y) is the
pdf of age at cancer diagnosis given birth year x and tumor onset time y. Under
competing risks, fI(aI − y|x, y) can be split into two crude densities,
fI(aI − y|x, y) = f cCDx(aI − y|x, y) + f cSDx(aI − y|x, y)
where
f cCDx(aI − y|x, y) = fCDx(aI − y|x, y)GSDx(aI − y|x, y)
and
f cSDx(aI − y|x, y) = fSDx(aI − y|x, y)GCDx(aI − y|x, y).
Here fCDx(aI − y|x, y) and GCDx(aI − y|x, y) are the p.d.f. and survival function
(s.f.) of TCDx, the sojourn time distribution, and fSDx(aI − y|x, y) and GSDx(aI −
y|x, y) are the p.d.f and s.f. of TSDx, time to PSA diagnosis, respectively computed as
an average over the point process of screening schedule and the outcomes of screening
tests. Distributional characteristics of the schedule process (intensity of utilization
of screening in the population) was estimated in Mariotto et al. (2007). Integrating
out the age at tumor onset y, we have the unconditional p.d.f. of age at diagnosis aI
fI(aI |x) = f cCDx(aI |x) + f cSDx(aI |x).
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Note that the unconditional p.d.f fCDx(aI |x) is a function of the age of the subject
while the conditional p.d.f fCDx(aI − y|x, y) is a function of the delay time defined
as tD = aI − y. Detailed expressions can be found in Tsodikov et al. (2006).
3.2.2 Z-specific incidence model
We use r.v. Z to denote four possible combinations of binary stage and grade
classifications (Localized/Reginal Stage, Low Grade)=LL, (Localized/Reginal Stage,
High Grade)=LH, (Distant Stage, Low Grade)=DL, (Distant Stage, High Grade)=DH.
Disease stage is dichotomized into the local-regional (LR) stage and distant (D) stage.
Disease grade is divided into well or moderate (WM) differentiated (low grade) and
poorly differentiated or undifferentiated (PU) disease (high grade). Generally, Z can
be any multivariate mark on the cancer incidence process. The Z-specific incidence
model describes the probability of being diagnosed with prostate cancer at a certain
age and with specific stage and grade z. Conditional on birth year x, age of tumor
onset y, and age of tumor diagnosis aI , the probability of being diagnosed with stage
and grade z was modeled using mixed multinomial logit model (Chefo and Tsodikov,
2009). Missing data include the delay time between tumor onset and diagnosis (a
backward recurrence time) and the mode of diagnosis. Calendar time and age are
treated as fixed effects covariates. Using the Z-specific incidence model we predict
the conditional (multinomial) distribution of z, fI(z|x, aI) given the cohort x, inci-
dent age aI . Note that fI(z|x, aI) is a conditional average over and tumor onset age
Y , and the mode of diagnosis IScr =1 if SDx and =0 if CDx. Using the model we
can update the distribution of Y given the information available at diagnosis.
The conditional distribution of the age of tumor onset Y can be written as
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Y ∼ fI(y|x, aI , z) =
fI(aI , z, y|x)
fI(aI , z|x)
=
fI(z|x, aI , y)fI(aI |x, y)fo(y|x)∫ aI
0
fI(z|x, aI , y)fI(aI |x, y)fo(y|x) dy
.







fI(z|x, aI , y)fI(aI |x, y)fo(y|x) dy
fI(aI |x)
.
The Z-specific incidence is given by
(3.2) λI(aI , z|x) = λI(aI |x)fI(z|x, aI),
where λI(aI |x) is the marginal incidence, and fI(z|x, aI) serves as a factor partition-
ing it into the z-specific components.
3.2.3 Lead-time
Lead-time measures the amount of time the point of diagnosis is advanced due to
screening. It represents the period between SDx and real or counterfactual CDx. For
a clinically detected patient, the lead-time is zero, and its distribution has a mass
at zero reflecting the proportion of CDx among all diagnoses. It is an important
factor in cancer survival presenting a guaranteed survival benefit (patients cannot
die before symptoms appear). For an incident patient with characteristics (x, aI , z),
the updated distribution of lead-time is
fLT (s|x, aI , z) =






fLT (s, aI , z|x) =
∫ aI
0
fo(y|x)fI(z|x, aI , y)

GSDx(aI − y|x, y), (s = 0)
fSDx(aI − y|x, y), (s > 0)
fCDx(aI−y+s|x, y) dy,
fI(aI , z|x) =
∫ aI
0
fI(z|x, aI , y)fI(aI |x, y)fo(y|x) dy.
The expressions above integrate the subject’s history over the unobserved age at
onset and mode of diagnosis. The history includes onset, observed diagnosis SDx
or CDx, presentation z at observed diagnosis, and counterfactual CDx if observed
diagnosis is SDx). Lead-time equal to 0 implies that the person had a CDx while
lead-time > 0 means that the person had an SDx.
3.2.4 Disease progression model and the null hypothesis of treatment effect
The disease progression model estimates the probability of disease progression
during the lead-time in the absence of treatment. Let the vector
VIScr = (aIScr , zIScr)
be the disease presentation at diagnosis indexed by the mode of diagnosis. For a
screen-detected patient we have V1 at the observed SDx and V0 at the counterfac-
tual CDx. Note that as a result of the Z-specific incidence model (3.2) we have a
model for the marginal distribution of V when the mode of diagnosis IDx is random
(unobserved).
Disease progression between SDx and CDx can be characterized by the transi-
tional distribution fV (V0|V1, x) describing the p.d.f. of the disease presentation at
counterfactual CDx (V0) conditional on the observed presentation V1 at SDx and the
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birth cohort x. We can expand fV as
(3.4) fV (V0|V1, x) = fLT (tLT |a1, z1, x, tLT > 0)pb(z0|z1, tLT ),
where the lead-time tLT for the disease detected by the test
fLT (tLT |·, tLT > 0) =
fLT (tLT |·)
1− fLT (0|·)
is conditional on SDx that is equivalent to a positive lead-time, tLT > 0. Here
pb(z0|z1, tLT ) are the baseline progression probabilities. While generally, pb may de-
pend on the lead-time, in the data analysis example we assume they are independent
of tLT . This gives a set of unknown parameters pb(z0 = j|z1 = i) = pbij, where i ≤ j,
i, j = 1, . . . , 4 go over the four categories of stage and grade z, that is summarized as
a progression probability matrix (PPM) in (Table 3.1). The fact that i ≤ j reflects
the assumption that cancer cannot regress.
The main difficulty in estimating the PPM is rooted in the fact that CDx and
SDx are not observed on the same subject. So there is no direct subject-specific data
on the disease progression.
To estimate the PPM, we first formulate the null hypothesis of treatment effect.
Under the null hypothesis of treatment effect the baseline PPM probabilities pb are
not affected by treatment applied at the point of SDx. If treatment had an effect,
the baseline probabilities pbs would be transformed by a categorical regression model
with treatment as a covariate and pb corresponding to the baseline of no treatment.
In the extreme, treatment applied at the point of SDx may completely prevent cancer
progression in which case PPM would be an identity matrix (stage and grade are
frozen at SDx and carry over unchanged to the point CDx). This introduces the so-
called stage-shift resulting in distant stages being prevented by screening when cancer
is detected while it is still localized and progression is arrested by treatment. It is this
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stage shift assumption that is at the root of the mortality benefit of screening (and
treatment) assumed in many models of cancer mortality in the presence of screening.
Now consider two model predictions in the following two counterfactual scenarios:
1. z-specific Incidence λI(a, z|¬S) under no screening (¬S, zero screening sensitiv-
ity); and
2. the model predicted z-specific incidence λI(a, z|iS) as if screening were ignored
(iS) and the patient was left undiagnosed until his lead-time expired.
While the first scenario does not involve the PPM and is expressed by the z-specific
incidence model prediction (3.2) under zero screening sensitivity, the second coun-
terfactual scenario uses PPM to predict stage and grade at the end of the lead-time.
The absence of the stage-shift is expressed as the equality
(3.5) λI(a, z|¬S) ≡ λI(a, z|iS),
where ≡ denotes a uniform equality over a, z represents the first part of the null
hypothesis of the treatment effect. The equality (3.5) represents the first part of the
null hypothesis of treatment effect where λI(a, z|iS) is computed using the baseline
probabilities pb. In the case of more general progression models, not necessarily
formulated in terms of PPM, (3.5) still represents the first part of the null hypothesis
expressing the general equivalence of ignored screening iS, zero screening sensitivity,
and zero treatment effect. In other words there is no difference between no screening,
screening with zero sensitivity, or screening combined with ineffective treatment as
far as the disease presentation at real or counterfactual CDx goes.
The second part of the null hypothesis is the similar equality for cancer mortality
that remains beyond the scope of the present paper.
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To estimate the PPM we treat (3.5) as an equation for the unknown pb parameters.
The idea is to deduce the disease progression model from the marginal one by making
the two counterfactual predictions as close as possible. The target function to be
minimized for the estimate of the disease progression model, l, can be written as the
Poisson likelihood ”distance” (3.6) between the two predictions by treating one of
them as ”observed” data (¬S), and the other as expected (iS).








P (a, t, z) {λI(a, z|¬S) log λI(a, z|iS)− λI(a, z|iS)}
where P (a, t, z) is the population count with age a, stage and grade z, in calendar
year t, and λe is deduced from the corresponding joint pdf






f(a1, z1|S)fLT (a− a1|z1, a1)pb(z|z1, a− a1)da1
+f(a, z|S)× fLT (0|a, z).
The latter expression represents an incident cancer under iS as either a real CDx
with zero lead-time (second term) or a counterfactual one in which case possible
presentations at SDx prior to the counterfactual CDx are entertained in the first
term of the sum, analogous to backward Markov equations.
Standard errors of the estimates are obtained by bootstrap.
The progression model was fitted to SEER data. Only 5% to 6% patients progress
in stage/grade respectively in the localized stage, low grade group at SDx. No
progression from the best category (local stage and low grade) to the worst category
(distant stage and high grade) is observed, perhaps due to the long time frame
required for such a big transition compared to the lead-time. Local stage high grade
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Table 3.1: Results of Estimated Progression Probability Matrix (PPM) and 95% C.I.
Counterfactual
Clinical Diagnosis
Stage/Grade LR/L(1) LR/H(2) D/L(3) D/H(4)
LR/L(1) pb11=0.893 pb12=0.051 pb13=0.056 pb14=0
(0.879,0.906) (0.039,0.062) (0.049,0.064) (0,0)
Screening LR/H(2) 0 pb22=0.717 0 pb24=0.283
Diagnosis (0.676 0.757) (0.243 0.324)
D/L(3) 0 0 pb33=1 pb34=0
(1,1) (0,0)
D/H(4) 0 0 0 1
Stage: LR=Local/Regional, D=Distant. Grade: L=Low(WM), H=High(PU).
patients are more likely to progress. About 28% potentially progress to distant
stage. There is no grade progression in the distant stage patients likely because their
lead-time is too short for the grade to change.
3.2.5 Survival model
The survival model G describes the time spent in the clinical state conditional on
the age of incidence aI , year of diagnosis t, (t = x+ aI), and stage and grade z.
Two adjustments were made in survival model during the PSA era. First, lead-
time adjustment was made to make sure survival times are always measured from the
time of clinical diagnosis to time of death implying a guaranteed lead-time benefit.
Additionally, survival is conditional on the stage and grade at the time of the clinical
diagnosis, the latter being unobserved if the patient is screened-detected. The stage
and grade progression during the lead-time was described by the disease progression
model in section 3.2.4.
The survival function from the time of diagnosis to time of death (ts) can be
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written as
G(ts|x, aI , z) = GLT (ts|x, aI , z)






pb(z0|z)fLT (s|x, aI , z)Gb(ts − s|x, aI + s, z0) ds(3.7)
where Gb is the baseline survival function measuring survival time from the clinical
diagnosis to death.
All three terms on the right represent mutually exclusive possibilities. The first
term is a survival function of the lead-time GLT that represents guaranteed survival
up to ts if the lead-time is at least as large as ts, i.e. the patient does not die from the
disease before he develops symptoms. The second term is the survival contribution
of symptomatic diagnoses with the probability of clinical diagnosis (the probability
of lead-time is zero) as the weight. The last term represents cancer progression or
non-progression from the presentation at SDx to projected CDx, and survival with
possibly a more advanced stage thereafter.
3.3 Predictions
We use our model to predict key population and subject-specific characteristics
of prostate cancer.
3.3.1 Natural history of Prostate Cancer in US
We present population predictions of major natural history events such as lifetime
risk, mean age at event, and mean time between events. In this study, we look at
scenarios under the null hypothesis of no treatment.
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Cancer onset
Conditional on birth year x, let fo be the p.d.f. of Y , the time from birth to
tumor onset (age at tumor onset), and GOC be the s.f. for TOC , the time from birth
to other causes of death. Let y and a∞ denote the age at tumor onset and the
maximal lifetime, respectively. The lifetime risk of tumor onset can be written as a
crude cumulative probability of tumor onset Y occurring before death due to other
causes (OC). The mean age of tumor onset is computed as a conditional expectation













Using the definition described in 3.2.1, let the crude density f cCDx(aI |x) correspond
to clinical diagnosis given birth year x and age of diagnosis aI . The lifetime risk and
the mean age of clinical diagnosis (CDx) under early detection can be computed
using the the cumulative crude probability and the conditional expectation similar
to (3.8). Conditional on birth year x, let f cCDx(aI , z ∈ D|x) be the joint crude density
that represents incidence at age aI with distant stage and fI(aI |x) = f cCDx(aI |x) +
f cSDx(aI |x) be the p.d.f. of the overall incidence at age aI . Replacing f cCDx(aI |x) in
equation (3.9) with f cCDx(aI , z ∈ D|x) and fI(aI |x) = f cCDx(aI |x) + f cSDx(aI |x), we
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have the lifetime risk and mean age for metastatic clinical diagnosis (Met CDx) and
overall diagnosis (CDx or SDx), respectively.











CDx(aI |x)Goc(aI |x)daI∫ a∞
0
f cCDx(aI |x)Goc(aI |x)daI
2. Metastatic clinical diagnosis (Met CDx)
• lifetime risk ∫ a∞
0







CDx(aI , z ∈ D|x)Goc(aI |x)daI∫ a∞
0
f cCDx(aI , z ∈ D|x)Goc(aI |x)daI













4. Mean years from onset to tumor diagnosis
The time from tumor onset to tumor diagnosis aI − y is called the delay time
(tumor age). For the unscreened population, the delay time is the same as the
sojourn time, TCDx. For screened the population, the delay time is the minimum
of TCDx and TSDx. Mean years from onset to tumor diagnosis can be computed












fo(y|x)f(aI − y, z|x, y)Goc(aI |x)daIdy
where
f(aI − y, z|x, y) =

f cCDx(aI − y|x, y), CDx.
f cCDx(aI − y, z ∈ D|x, y), Met CDx.
fI(aI − y|x, y), CDx or SDx.
Cancer death
Conditional on birth year x, the marginal survival function GM(aM |x) of age aM
at cancer-specific death (s.f. of mortality) can be written using the convolution of







fI(z|x, aI)G(aM − aI |x, aI , z)daI
+GI(aM |x).(3.13)
The first part of the equation describes the probability of a man who has prostate
cancer diagnosed at the age aI (before age aM) with stage and grade z at the time
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of diagnosis, to survive at least (aM − aI) years after the diagnosis. The second part
of the equation represents the probability for a man who has never been diagnosed
with prostate cancer. Similar to equations (3.8), we can compute lifetime risk and









aMfM(aM |x)Goc(aM |x)daM∫ a∞
0
fM(aM |x)Goc(aM |x)daM
3.3.2 Risk of adverse events for local-regional screen-detected patients
In this section we provide subject-specific predictions for a PSA-detected man
diagnosed with localized-regional stage.
Let ai and zi, i = 0, 1 denote age and stage/grade at CDx and SDx, respectively.
For a man diagnosed by the PSA test, the disease presentation at CDx is unobserved.
Conditional on the disease presentation at SDx (a1, z1) and the fact that the patient
was detected by screening, the p.d.f. of the lead-time distribution is
(3.15) fLT (s|x, a1, z1 ∈ LR, TLT > 0) =
fLT (s|x, a1, z1 ∈ LR)
1− fLT (0|x, a1, z1 ∈ LR)
,
where s = a0 − a1, a0 ≥ a1 is the lead-time argument (section 3.2.3). Also the
probability of stage and grade progression during the lead-time can be estimated
using the PPM (Table 3.1).
1. Clinical diagnosis (CDx)
Conditional on birth year x and age at diagnosis a1, the lifetime risk of coun-
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fLT (a0 − a1|x, a1, z1 ∈ LR, TLT > 0)Goc(a0|x)da0.
The event of counterfactual CDx defines the cancer as a relevant one (as opposed
to overdiagnosed) that would eventually present symptoms without screening.
2. Metastatic clinical diagnosis (Met CDx)




fLT (a0 − a1|x, a1, z1 ∈ LR, TLT > 0)pb(z0 ∈ D|z1 ∈ LR)Goc(a0|x)da0.
3. Prostate cancer death
In addition to the potential clinical diagnosis, the chance that the man dies
from prostate cancer in his lifetime can be expressed using the survival time
ts measured from the age of cancer diagnosis a1 to age of cancer death aM
(ts = aM − a1) as discussed in section 3.2.5. Conditional on SDx (TLT > 0), the
survival function for the PSA-detected man at the age of a1 and with stage/grade
z1 is






pb(z0|z1 ∈ LR)fLT (s|x, a1, z1 ∈ LR)Gb(ts − s|x, a1 + s, z0) ds.






f(aM − a1|x, a1, z1 ∈ LR)Goc(aM |x)daM
3.4 Data analysis and results
Our analysis was performed using the SEER9 database from 1973 to 2000 which
contains more than 350,000 cases of prostate cancer from 9 registries: Atlanta, Con-
necticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget
Sound, and Utah. Parameters (except the PPM) in our model were estimated using
maximum likelihood methods. Distributions entering the z-specific incidence model
were estimated in our previous study (Tsodikov et al., 2006; Chefo and Tsodikov,
2009).
Predictions of key prostate cancer population characteristics in US are summa-
rized in Table 3.2. Numbers listed on the table are averages over the 50-84 age
window (a typical age interval for SEER-based statistics) and 1975 to 2000 calendar
year window.
On average, the lifetime risk of a man developing prostate cancer is 20%. Among
men who develop prostate cancer, their average age at tumor onset is 72 years. If
there were no screening, the average lifetime risk of prostate cancer clinical diagnosis
with any stage and with distant stage would be 10% and 1%, respectively. Both
groups have same average age at diagnosis of 81. Under screening, the average life-
time risk of CDx, Met CDx, and any diagnosis are 6%, 1%, and 15%, respectively.
The average age at diagnosis is 80 for a clinically detected case and 75 for any mode
of diagnosis. The mean time from onset to diagnosis is 6-7 years for CDx, 3-4 years
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Table 3.2: Predictions of key prostate cancer natural history events
Mean years
Lifetime risk(%) Mean age(years) from onset
Cancer onset 20 72
Cancer diagnosis
- CDx 10a/6b 81a/80b 7a/6b
- Metastatic CDx 1a/ 1b 81a/80b 4a/3b
- SDx or CDx 15 75 6
Cancer death 4a/ 4b 81a/81b 10a/10b
a, b indicates events under scenarios without and with screening, respectively.
for Met CDx, and 6 years for SDx or CDx cases. The average delay time (time from
the tumor onset to diagnosis) is shorter for Met CDx patients compared with the
average time from all cases (i.e. 7 vs. 4 years under no screening scenario). This
observation indicates that our partially specified model favors heterogeneity in tumor
aggressiveness, and more aggressive tumors are detected earlier due to their shorter
latency times. Also under the screening scenario, the lifetime risk of CDx is smaller
because some of them would be diagnosed earlier by screening. The lifetime risk of
death from prostate cancer is 4%. Among those men who die from prostate cancer,
the average age of death is 81 years old and it takes about 10 years from the tumor
onset. Without any treatments, the risks of cancer death are about the same for
screened and unscreened population.
In Table 3.3, we provide projected risks of adverse events for men diagnosed by
PSA with local-regional stage prostate cancer in 2000 using SEER data. The pre-
dictions are stratified by disease grade (low vs. high) and age groups.
For a PSA-detected local-regional stage prostate cancer case, the probability of
CDx within his lifetime is about 59% to 93% depending on the age at diagnosis.
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Table 3.3: Lifetime risk of adverse events for local-regional screened-detected patients
Metastatic
Stage/Grade Age group Clinical diagnosis clinical diagnosis Prostate cancer death
50-54 93 6 28
55-59 90 5 29
60-64 86 5 30
LR/L 65-69 80 5 30
70-74 74 4 28
75-79 66 4 24
80-84 59 3 17
50-54 90 30 60
55-59 90 26 63
60-64 86 24 62
LR/H 65-69 80 23 59
70-74 74 21 53
75-79 66 19 45
80-84 59 16 33
Regardless of the grade at disease detection, patients diagnosed at a younger age are
more likely to develop symptoms and be detected clinically within their lifetime. Risk
of being diagnosed with metastatic disease clinically or the risk dying from prostate
cancer within lifetime are also decreasing by age of diagnosis. For high grade PSA-
detected patients, the chance of being dignossed later with metastatic disease if left
untreated is almost 5 times higher when compared with low grade patients (16-30%
in high grade vs. 3-6% in low grade). They have about twice the chance of dying
from the prostate cancer in their lifetime (33-60% in high grade vs. 17-28% in low
grade).
3.5 Discussions
We presented an analytical statistical model for the joint disease presentation
at potentially two diagnoses per subject, SDx and CDx, the latter being counterfac-
tual. The model combines explicit mechanistic assumptions with a partially specified
disease progression mechanism.
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We formulated the null hypothesis of the treatment effect on the stage-shift as the
equality of stage/grade-specific cancer incidence predictions under two counterfactual
scenarios of zero screening sensitivity and ignored screening applied to the PSA era.
This understanding allowed us to devise an estimation procedure for the progression
probabilities for the screen-detected cancer patient despite the absence of longitudinal
observations of cancer progression within the subject.
The model is explicit enough as it shows the points where treatment may have
an effect. The model can be used to relax the traditional stage-shift assumption by
incorporating the treatment effect into a nominal or ordinal model for the progression
probability matrix. Another point of application of treatment effects is the treatment
by lead-time interaction and the treatment main effect acting on the survival function
of time post counterfactual CDx resulting in a complex frailty model. Estimation
of such treatment effects would require fitting the model jointly to survival and
incidence data.
The minimization of the distance between the two counterfactual incidence pre-
dictions to estimate the PPM will not exactly satisfy (3.5). In our data analysis, the
quality of the approximation is good for all practical purposes. The fact that only an
approximate model is available is a consequence of an independent model formula-
tion for the progression probabilities and the marginal V that could be inconsistent
with each other. The alternative would be to define the latent cancer growth and
progression process explicitly and fit it to the observed data. However, the mech-
anism of prostate cancer progression (i.e. whether cancer progresses in grades or
whether the grade is fixed at onset) is very much under debate by cancer biologists.
In addition strong unjustified assumptions would have to be made to assure identifi-
ability of the complex latent process model from the aggregate observed population
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data. Pursuing a robust partially specified model and leaving the exact mechanism
of cancer progression open seems to be a better approach.
Nevertheless, some elements of mechanistic modeling of the mechanism of tumor
growth and cancer detection may be worth pursuing. For example, in table 3.2,
the met CDx patients have a shorter delay time compared with all CDx patients
(i.e. 4 vs. 7 years under no screening scenario). This suggests that more aggressive
tumors tend to be detected earlier. The model could include the heterogeneity of
tumor growth rates in some form. This indicates that the so-called early onset
prostate cancers (cancer diagnosed before 55) may represent a subset enriched with
aggressive tumors in line with some recent genetics research targeting such patients
in search for markers of the aggressive disease.
CHAPTER IV
Mortality Model for Prostate Cancer
4.1 Introduction
There is growing interest in cancer screening programs. The goal of any screening
program is to diagnose patients early so they would be detected in a more favorable
stage and have better prognosis for treatment. The effect however cannot be eval-
uated directly using patient-specific data because of the favorable shift in stage of
the disease and survival post-diagnosis that would be occurring with screening even
if treatment were of no benefit. Prostate-specific antigen (PSA) test was approved
by the U.S. Food and Drug Administration (FDA) in year 1988 and it is commonly
used by physicians in routine physical exams to screen for prostate cancer in men at
risk. However, survival benefit is a matter of debate. Although USA prostate can-
cer mortality has dropped more than 30 percent since early 1990, coincidently after
the introduction of PSA, there has long been a controversy and speculations on the
survival benefit of prostate cancer screening. Several ecological studies conducted
in United State and Europe found no conclusive evidence to prove the association
between the intensity of PSA screening and mortality reduction (Shaw et al., 2004;
Collin et al., 2008). One way to assess whether PSA screening contribution to recent
mortality decline is by conducting randomized screening trials. Such trials require
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large amount of patients and long term follow-up to be able to have sufficient power
to compare outcomes. Three large-scale randomized screening trials, the Prostate,
Lung, Colorectal and Ovary cancer trial (PLCO) conducted by National Cancer
Institute (NCI) in United State, the European Randomized Screening for Prostate
Cancer (ERSPC), and the Comparison Arm for ProtecT study in UK (CAP, 2009),
are on-going to test whether PSA screening tests reduce the mortality of prostate
cancer but it is still too early to make final conclusions. Interim results from PLCO
found no effect of prostate cancer screening (Andriole et al., 2009) while ERSPC
showed some survival benefit from screenings (Schroder et al., 2009). Besides a sta-
tistical convenience approach of testing for benefit in a screening trial will make the
effect estimate specific to the trial populations and its generalizability to populations
with a different pattern of screening would be a challenge.
The questions can be addressed by statistical modeling. Mathematical and sim-
ulation models have been developed in the past to evaluate screening programs.
Oftentimes cancer progression is modeled using a semi-Markov stochastic process.
Lee and Zelen (2008) developed a general probability model and used it to assess
the role of screening programs in breast cancer mortality. The model derives the
benefit of screening from more favorable stage distribution of screen-detected cases
vs. the clinically diagnosed cases. The assumption that stage at screening diagnosis
(SDx) determines the prognosis has been referred to as the stage-shift. In prostate
cancer, watchful waiting is a legitimate ”treatment” option for patients whose per-
ceived chance of dying from prostate cancer is low. The stage-shift is essentially
an interaction effect between early detection and curative treatment based on the
assumption that the treatment applied at SDx prevents stage progression, and a
patient who would be in an advanced stage at clinical diagnosis (CDx) is prognosti-
65
cated using early stage survival having been detected at an early stage by screening.
This assumption may be problematic particularly if the patient receives no curative
treatment on watchful waitings.
This paper was motivated by the following refinements of the general stage-shift
mortality model:
1. We wanted to use cancer registry data, where screening schedules are unob-
served, to specify the inputs for the prediction of mortality. Therefore, we treat
screening schedules as an unobserved point process with known distribution.
This makes the mortality prediction a functional of screening policy as condi-
tioning on intermediate outcomes is avoided.
2. The prediction of survival for a patient detected with cancer is based on updat-
ing the distribution of this patient’s natural history of the disease conditional
on age, stage and grade observed at diagnosis, recognizing that the mode of
diagnosis (SDx, or CDx) is not observed in SEER data. Treatment effects in-
teract with the latent natural history.
3. We used an categorical model for treatment allocation based on patient’s infor-
mation available at diagnosis that modeled treatment patterns over time.
4. We provide a flexible stage-shift approach to modeling and estimating the chance
of stage progression between SDx and the counterfactual CDx (one that would
occur if the results of screening were ignored). Patients who progress in stage
or grade by the end of the lead time will have advanced stage/grade survival.
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One dimension of the screening and treatment interaction is how the treatment
affects the stage-shift and the chance of cancer progression.
Section 4.2 will describe the main elements of the mortality model. In Section 4.3
we apply the model to analyze US prostate cancer mortality. Finally, Section 4.4




Our basic model used the classical three-state chronic disease model. Three states,
disease-free state, pre-clinical state, and clinical state, represent the progression of
the natural history of the disease, and transitions are irreversible. The disease pro-
gression with respect to stage and grade is only partially specified as will be described
in Section 4.2.4. The disease-free state is measured from the time a man turns fifty
to the time of the tumor onset. For population under screening, the screening diag-
nosis and the clinical diagnosis are two competing risks operating at the pre-clinical
state. The pre-clinical state is calculated from time of tumor onset to time of clinical
diagnosis or screening diagnosis whichever comes first. The clinical state describes
the survival time from the time of diagnosis to the time of death or last follow up.
4.2.2 Mortality Model
Conditional on birth year x, cancer mortality is a hazard function, λM , of the age




where fM(aM |x) is the probability density function (p.d.f.) and GM(aM |x) is the sur-
vival function (s.f.). For a man from the birth cohort x, the probability of surviving
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fTx(Tx|x, aI , z)G(aM − aI |x, aI , z, Tx)daI
+GI(aM |x)(4.1)
The first part of the equation describes the probability for the man, who had
prostate cancer diagnosed at the age aI (before age aM) with stage and grade z,
received treatment Tx at the time of diagnosis, and survived at least (aM −aI) years
after the diagnosis. The second part of the equation represents the probability for the
man who has never been diagnosed with prostate cancer. Mortality is a convolution of
five models addressing the development of the disease under screening and treatment
interactions: Marginal incidence(section 3.2.1), Z-specific incidence (section 3.2.2),
treatment(section 4.2.3), disease progression between SDx and counterfactual CDx
(section 4.2.4), and survival models (section 4.2.5). The latter two models are used to
specify the s.f. G in equation 4.1 describing survival time post real or counterfactual
CDx conditional on stage and grade at that point .
4.2.3 Treatment Model
The treatment model describes the probability of receiving a certain treatment
combination at the time of cancer diagnosis. Using SEER data, we classified treat-
ments into three major categories: Conservative Management (CM), Radiation Ther-
apy (RT), and Radical Prostatectomy (RP). Hormone Therapy (HT) is commonly
used as an adjuvant therapy following one of those three primary treatments, RT
most commonly. Note that HT information is not available in cancer registries,
hence we used a two-stage model to predict treatment allocations. In the first
stage, we modeled the probability of receiving one of the three treatments defined
in SEER data conditional on birth year x, age of diagnosis aI , and grade using
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multinomial logit model. In the second stage, we conditioned on the treatment
obtained from the first stage, birth year x, age of diagnosis aI , and grade and
used logistic regression to model the probability of receiving the additional adju-
vant hormone therapy. The second stage model was fitted to CaPSURE data (
http://urology.ucsf.edu/capsure/overview.htm)
By combining first and second stage, we can obtain the probability of actual treat-
ment received given birth year x, age of diagnosis aI , and grade.
4.2.4 Disease Progression Model
The disease progression model estimates the probability of disease progression
during the lead time in the absence of treatment. Assuming no stage and grade
regression, the disease presentation at the end of the lead time is given by a set
of baseline transition probabilities, pbs, that can be summarized as a progression
probability matrix (PPM) (Table 3.1).
The impact of treatment can be introduced into the transition probabilities pb
using a cumulative logit (k > 2) or a logistic regression (k = 2) model working
with a row of the PPM matrix. In the logistic regression model, let pb be the
baseline transition probability, and ηTx be the treatment effect (odds) on the baseline
transition probability. The transition probability given the treatment effect is
(4.2) pij = Pr(z0 = j|z1 = i, Tx) =
pbijηTx
pbij(ηTx − 1) + 1
, j > i,
where z0,1 is stage-grade response at CDx, and SDx, respectively.
In the cumulative logit model, let cpb be the cumulative baseline transition proba-
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bility. The cumulative transition probability given the treatment effect is
cpij = p(z0 ≤ j|z1 = i, Tx) =
cpbij/ηTx
cpbij(1/ηTx − 1) + 1
, j ≥ i(4.3)
and pij = cpij − cpi(j−1).
When there is no treatment effect on the probabilities (i.e. ηTx = 1), pij = pbij.
When the treatment effect is really large (i.e. ηTx → 0), then PPM will become an
identity matrix corresponding to the full stage-shift when the stage and grade carry
over from the screening diagnosis to the counterfactual clinical diagnosis.
4.2.5 Survival Model
The survival model G describes the time spent in the clinical state conditional
on the age of incidence aI , year of diagnosis t, (t = x + aI), stage and grade Z,
and treatment Tx. As discussed in our earlier paper (Lee and Tsodikov, 2010), the
estimated treatment effect using the Cox PH model is biased under early detection
(with random lead time added to the survival time). In this paper, we propose two
approaches to assess the treatment efficacy using the full likelihood while accounting
for the heterogeneity and survival biases induced by the early detection.
Generalized Stage-shift Model
The Generalized stage-shift model is motivated by the traditional stage-shift
model by allowing disease progression during the lead time. Two adjustments were
made in the survival model during the PSA era. First, lead time adjustment was
made to make sure survival times are always measured from the time of clinical
diagnosis to time of death implying a guaranteed lead time benefit. Additionally,
survival is conditional on the stage and grade at the time of the clinical diagnosis,
the latter being unobserved if the patient is screened-detected. Three treatment ef-
fects were investigated in the model. The treatment main effect θTx describes how
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treatment affects post-lead time survival. The treatment effect applied to the dis-
ease progression (ηTx) measures how treatment prevents stage and grade progression
during the lead-time. Finally, even if the patient progresses during the lead time,
the one treated earlier is still better off than the one treated close to the point of
symptoms, and this is represented by the treatment by lead-time interaction effect,
θTx×LT in the s.f. G post real or counterfactual CDx. We did not model treatment
by early detection interaction effects in distant stage at CDx because the predicted
conditional lead time was too short to have an effect.
G(ts|aI , t, z, Tx) = GLT (ts|aI , t, z)






Pr(z0|z, Tx)fLT (s|aI , t, z)Gb(ts − s|aI + s, t, z0, Tx) ds(4.4)
and
Gb(ts − s|aI + s, t, z0, Tx, s) = G0(ts|aI , t, z0)θAgeθTxθTx×LT
where G0 is the model under a reference group under conservative management.
Calibration Model
An alternative approach to the Generalized stage-shift model is the Calibration
model. Similar to the stage-specific incidence model we use the delay time as a
frailty. Additionally, we use the mean lead time predicted given information ob-
served at diagnosis as a covariate for s.f. G. The latter aspect has motivated the
name “calibration” by analogy with measurement error models. With this model
integrating over future latent development is avoided which makes the computation
a little faster. The modeled treatment effects are conceptually similar to the Gener-
alized Stage-Shift Model. For instance, this model includes the treatment by expected
lead time interaction effect to assess the benefit of treatment under early detection.
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Replacing the latent lead time with the expected lead time allows us to avoid making
any assumptions on disease progression. The main treatment effect operates on the




s fLT (s|aI , t, z)ds
G(ts|aI , t, z, Tx) = G0(ts|aI , t, z0, Tx0)θAgeθSurrogateθTxθTx×ELT .(4.5)
4.3 Data Analysis and Results
Our analysis was performed using SEER9 database from 1973 to 2000 and pa-
rameters were estimated using maximum likelihood methods. It contains more than
350,000 cases of prostate cancer from 9 registries: Atlanta, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah.
All observed or predicted rates were adjusted for the US 2000 population age distri-
bution obtained from the Human Mortality Database(HMD), Max Plank Institute
for Demographic Research (2009). Figure 4.1 shows the observed and expected US
prostate cancer incidence λI(aI |x) by calendar year for men over 50. Prostate cancer
incidence showed an increasing trend over time before the PSA era followed by the
surge resulting from increased use of PSA tests after year 1988.
Figure 4.2 shows the predicted stage and grade distribution fI(z|aI , x) at diag-
nosis. The majority of prostate cancer patients are likely to be diagnosed in lo-
cal/regional stage and with low grade (WM). Getting older increases the chance of
being diagnosed in advanced stage. For patients diagnosed at the same age, those
who are diagnosed more recently have more favorable stage and grade distributions.
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Figure 4.1: Observed and expected incidence by year.
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Figure 4.2: Expected stage and grade distribution by age and year of diagnosis.
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Figure 4.3 and 4.4 show the probabilities of receiving particular treatments as used
by the model, by age of diagnosis, year of diagnosis, and grade using the multinomial
logit model. As seen in Figure 4.3, older patients are more likely to get conservative
management while younger patients tend to receive more aggressive treatments such
as radical prostatectomy (RP) or radio therapy (RT). The trends are similar for
both low and high grade patients. Figure 4.4 shows that the use of conservative
management (CM) was gradually decreasing over the years while radio therapy (RT)
became more popular in recent years. More radical prostatectomy procedures were
performed around year 95. This trend is more dramatic in low grade patients than
it is in high grade patients. Figure 4.5 shows use of hormone therapy (HT) stratified
by the primary treatment received, year of diagnosis, and grade (logistic regression
model). Use of hormone therapy increased in recent years particularly after RT.
Figure 4.6 shows the estimated mean lead time conditional on age, year, stage, and
grade at the time of diagnosis. The highest mean lead time occurs in men diagnosed
in localized stage at around the age of 70, in year 1992. Local/regional disease
patients have much longer mean lead time than distant stage patients. Regressing
lead time on stage is therefore essential. Within each stage, there are only small
differences between lower and higher grade patients.
Table 4.1 and 4.2 showed the estimated treatment effect under early detection
stratified by stage and grade. Assuming other covariates being equal, Radical Prosta-
tectomy (RP) is associated with a substantial reduction of the hazard of prostate-
specific death (65% - 86% in the Generalized Stage-shift Model, and 56% - 89% in
the Calibration model). Applying the cumulative logit formula in equation (4.3), the
Generalized stage-shift model showed that RP reduced the probability of disease pro-
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Figure 4.6: Mean lead time given stage, grade, age, and year of diagnosis.
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to 0.7%, LR/L to D/L from 5.6% to 0.6%, and L/H to D/H from 28% to 0%) but no
additional survival post lead-time benefits from treating patients early were found
as a result of variable selection. The result from the Calibration model also supports
the evideince of the RP by early detection benefit. Each additional year of mean
lead time predicted at the time of diagnosis will lower the hazard by additional 9%
to 24% for patients treated with RP.
Similar to RP, Radiotherapy (RT) worked better for local-regional stage high
grade patients (HR=0.53 and 0.56 in Generalized stage-shift model and Calibration
model, respectively), and it had an additional survival benefit by treating patient
early. Advancing treatment by each year will reduce the hazard of dying from the
prostate cancer by additional 3%. However, it has no advantage on preventing disease
progression according to table 4.1. In Calibration model, a moderate RT early detec-
tion interaction effect was found in local-regional stage patients (HR=0.82 and 0.89
for LR/L and LR/H, respectively). For Local regional stage low grade patients, the
combination of negative main treatment effect and the postive treatment expected
lead time interaction effect might be interpretated as the trend of Radiotherapy effect
improving with calendar time into the PSA era.
Figure 4.7 shows the observed and expected age-adjusted US prostate cancer mor-
tality for men over 50 using our models. The US prostate caner mortality increased
slightly from year 1980 to year 1990 and decreased more than 30% since. Both mor-
talities using survival function estimated from the Generalized stage-shift model and
the Calibration model predicted the US mortality well. As shown in table 4.1 and
4.2, a decrease in mortality resulted from increased uses of screening and advanced
treatments in recent years. Other conditions held equal, treating patients earlier may
further improve survival by preventing disease progression or increasing survival post
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Table 4.1: Estimated treatment effects by stage and grade in Generalized stage-shift model
Hazard ratio (HR)
LR/L LR/H D/L D/H
Treatment main effect, θTx
RT vs. CM 1.07 0.53 0.96 1.10
RP vs. CM 0.35 0.19 0.14 0.28
Treatment effect on
disease progression, ηTx
RT vs. CM 1.00 1.00 N/A N/A
RP vs. CM 0.11 0.00 N/A N/A
Treatment lead time
interaction, θTx×LT
RT vs. CM 1.00 0.97 N/A N/A
RP vs. CM 1.00 1.00 N/A N/A
Table 4.2: Estimated treatment effects by stage and grade in Calibration model
Hazard ratio (HR)
LR/L LR/H D/L D/H
Treatment main effect, θTx
RT vs. CM 1.40 0.56 0.96 1.36
RP vs. CM 0.46 0.19 0.11 0.12
Treatment expected lead time
interaction, θTx×ELT
RT vs. CM 0.82 0.89 N/A N/A
RP vs. CM 0.76 0.91 N/A N/A
Surrogate
Expected lead time 0.99 0.96 N/A N/A
Delay time 1.12 1.17 1.18 0.51
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the lead time in selected groups of patients.
4.4 Discussions
We have presented a hierarchical family of models synthesized into a causal model
for cancer mortality linking the mortality endpoint with the population trends of
treatment and screening utilization. The model is an analytical model based on
a mechanistic description of the history of disease development, partially specified
disease progression mechanism, and its interaction with screening and treatment. It
provides an assessment of the benefit of screening and treatment for US prostate
cancer mortality and explains the mortality decline in the PSA era.
We developed an estimate of survival adjusted for the lead time and the disease
progression between the point of screening diagnosis and the counterfactual clinical
diagnosis. Length-biased sampling is reflected in our conditional lead time distribu-
tion given the disease presentation at diagnosis. We were able to vary the stage-shift
assumptions of the early detection program by addressing the disease progression
after the screening diagnosis. This allowed us to question the traditional stage-shift
assumption that stage and grade at the time of screening diagnosis carries over to
the time of projected clinical diagnosis.
Both survival models we proposed were able to explain the mortality decline re-
sulting from the combined effect of screening and treatment for prostate cancer. A
more mechanistic model, the Generalized stage-shift model, is more specific about
how the treatment effect is helped by early detection. Because this model operates
on the counterfactual CDx scenario, it can be used to assess the effects of deferred
treatment of prostate cancer in early stage patients. There might be other selection
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Figure 4.7: Observed and expected mortality by calendar year.
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effects that can be incorporated into the more mechanistic Stage-shift model. One
example is a possible length biased effect on s.f. G post real or counterfactual CDx.
For the purpose of reproducing the population mortality and survival trends, the
Calibration model does an equally good job and is slightly less complex computa-
tionally.
We have shown that treatment and early detection effects were varied by treat-
ment types and the clinical characteristics of the disease. Answering how and when
to treat patients will be the key to help patients, physicians and policy makers make
the best decision to improve treatment outcomes while managing the quality of life
and to achieve overall cost-effectiveness. This avenue can be explored by incorpo-




The goal of any early detection program is to diagnose and treat patients early to
improve the prognosis of disease and improve treatment. While screening interven-
tion might enhance treatment and improve the survival outcome and quality of life
in some patients, it also has a profound impact on heterogeneity and the meaning of
clinical variables for newly diagnosed patients. Analyzing data using such a dynamic
population could be challenging.
Our study is motivated by the controversy of the benefit of PSA screening. We
propose an analytic joint statistical model based on the classical three-state chronic
disease model to assess the benefit of screening and treatment on US prostate cancer
mortality. We are able to relax the traditional stage-shift assumption and present
a new approach to estimate disease progression probabilities without direct within-
subject observations. We also develop an estimate of survival adjusted for the lead
time and the disease progression between the point of screening diagnosis and the
counterfactual clinical diagnosis. This allows us to quantify the stage-shift and the
treatment effect explicitly and model interaction between treatment and early de-
tection. The model can be applied to describe the latent natural history disease
characteristics and help newly diagnosed patients make decisions on cancer manage-
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ment based on information given at the time of the diagnosis.
In the study, we also demonstrate how the early detection affects the clinical
survival outcome and show how evaluating treatment effect using patients recruited
from screened population could lead to bias. In addition, we study the direction of
the bias and propose a meta-analytic approach to correct the bias.
While our study provides innovative methods and interesting findings, there are
limitations in the current approach. For example, the disease progression probability
in our model does not depend on the lead-time. This means that the probability of
disease progression after the screening diagnosis is the same no matter how far in
advance the disease is detected. Further study is needed to validate this assumption
and to develop new methods to include lead-time into the current setting.
We also make simplifying assumptions to study the lead-time bias on treatment
effect. Length bias, disease progression, and associated treatment effects are ignored
and should be incorporated in our future setting.
To fight cancer and reduce the burden of cancer, it is important to continue
searching for more effective treatments and utilizing early detection programs. Cur-
rently, treatments are mainly evaluated using randomized clinical trials (RCT) and
other follow-up studies, while the early detection of the disease and its benefits are
evaluated using population data, observational studies, and screening trials. How-
ever, estimating benefits from a single data source and study design are vulnerable
to population heterogeneity due to unmeasured or unknown factors and selection
effects. For example, cancer registries (i.e. SEER) have less detailed representa-
tion of disease-specific clinical characteristics while clinical databases often miss on
population based processes, including utilization of diagnostic tests in the specific
population from which the study group was recruited. Besides, limited availability
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of raw data from RCT often provide only a summary measure of the observed effect
and its variability obtained by using a statistical convenience model.
We believe that it is not possible to generate valid predictions of treatment effec-
tiveness while restricting the analysis to a particular study design or dataset. We
need to continue to develop new methodology based on the joint analysis of multiple
sources of data under various study designs providing information on heterogeneity,
unmeasured factors, and treatment outcomes.
Last but not least, the mechanistic models presented in this thesis are amenable to
the introduction of dynamic deferred treatment regimen. The paradigm of detecting
and treating cancer as early as possible is definitely not adequate in prostate cancer
because of the massive overdiagnosis of the disease and diminished quality of life due
to treatment. A sensible strategy of balancing the risks, quality of life, and costs
lies in making treatments dynamic and deferring treatment until some indication of
disease progression. Providing the mechanistic basis for disentangling the causality
of such studies is an exciting future development for the proposed models.
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